Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Epigenetic Priming for Immune Therapy in ER-Positive Breast Cancer in Biomarker Select Population

NCT04190056 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT04190056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04190056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Epigenetic Priming for Immune Therapy in ER-Positive Breast Cancer in Biomarker Select Population
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Terminated
Start date
March 11, 2021
Completion date
June 15, 2023
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, prognostic stage iv breast cancer ajcc v8